Proteome-Focused ProFound Emerges From Flagship Pioneering

The company says its platform technology has uncovered “tens of thousands” of previously undiscovered proteins.

ProFound raised $75m from Flagship Pioneering to develop its proteomics platform technology • Source: Shutterstock

ProFound Therapeutics is planning to do a major expansion over the course of the next year as it emerges from Flagship Pioneering. The new firm is exploring a wide variety of proteins to enable novel therapeutics in areas like rare disease, immunology and oncology.

The company made its debut on 26 May with $75m in funding from Flagship Pioneering, where it was founded in 2020, built around the in-house ProFoundry platform and the idea that while the Human Genome Project found only 20,000 protein-coding genes, there is

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

AbbVie On MFN: ‘We Have To Take It Seriously’

 

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.